SAVANNAH, Ga. -- One year after starting efgartigimod (Vyvgart) treatment, most generalized myasthenia gravis (gMG) patients ...

The findings, presented at the Myasthenia Gravis Foundation of America (MGFA) session of the American Association of ...

(NASDAQ:ARGX – Get Free Report) had its price objective increased by research analysts at Citigroup from $512.00 to $635.00 ...

Revenue Growth: argenx displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue ...

A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with ...

Two genes were shown to be significantly associated with higher prevalence of myasthenia gravis (MG), a relatively rare autoimmune disease.

The investigational monoclonal antibody nipocalimab is associated with significant improvement in patients with generalized ...

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on RNAC stock, giving a Buy rating today. Uy Ear has given his Buy rating ...

Investigational nipocalimab lessened disease severity in generalized myasthenia gravis (gMG), the phase III Vivacity-MG3 ...

Myasthenia gravis (MG) is an antibody-mediated chronic neuromuscular disorder leading to fluctuating weakness and early muscle fatigue, with limited treatment options available. In MG, such as other ...